secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nano Dimension Ltd. (NNDM)
CIK:        0001643303
Form:       8-K
Filed at:   2026-06-17T20:05:32+00:00
Accession:  0001104659-26-075126
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nano Dimension provides update on proposed Infinite Epigenetics acquisition, values company at net cash plus 20% premium
--------------------------------------------------------------------------------

- Infinite Epigenetics is a commercial diagnostics platform with CLIA-certified lab, >120K samples, and >7,500 healthcare providers.
- Deal values Nano at net cash plus 20% premium; capital to accelerate commercialization and biological AI platform development.
- Nano responds to Murchinson Ltd. criticisms, highlighting board's rigorous review and alignment with shareholder interests.
- Infinite's AI platform uses proprietary DNA methylation data (one of world's largest private datasets), targeting >$90B chronic disease market.
- No transaction-driven compensation for Nano board; shareholders will vote on definitive agreement once finalized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1643303/000110465926075126/0001104659-26-075126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1643303/000110465926075126/tm2618166d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-075126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer